You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Causes of death among HIV-infected women followed in the MTCT-Plus program and treated with NVP-based HAART.

From: Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire

# CD4 count* cells/mm 3 Pregnancy at HAART initiation Regimen* Cause of death Time of death** (months) History of SAEs Description of SAEs Time of occurrence of SAEs** (months)
1 253 No AZT/3TC/NVP Mulitple myeloma 26.7 Yes Neutropenia grade 3 7.2
2 241 No AZT/3TC/NVP Hepatitis B 24.6 Yes Hepatotoxicity grade 3 24.2
3 332 No AZT/3TC/NVP Hepatitis B 13.3 Yes Anaemia grade 4 1.2
4 230 No AZT/3TC/NVP Unknown 24.9 Yes Neutropenia grade 4 9.2
5 271 Yes AZT/3TC/NVP Severe anaemia 3.7 Yes Anaemia grade 4 3.4
6 250 No AZT/3TC/NVP AIDS terminal 14.0 Yes Neutropenia Grade3 4.6
7 193 No AZT/3TC/NVP Cerebral malaria 20.8 Yes Rash grade 3 0.7
8 39 Yes AZT/3TC/NVP AIDS terminal 10.6 Yes Rash grade 3 2.0
9 170 Yes AZT/3TC/NVP AIDS terminal 20.4 No   
10 186 Yes d4T/3TC/NVP Eclampsia 1.8 No   
11 7 No AZT/3TC/NVP Pneumonia 6.9 No   
12 226 No d4T/3TC/NVP Renal tumor 2.0 No   
13 121 No AZT/3TC/NVP Cerebral malaria 10.0 No   
14 84 Yes AZT/3TC/NVP Fever 9.8 No   
15 24 No AZT/3TC/NVP Meningitis 7.4 No   
16 288 Yes AZT/3TC/NVP Gastric perforation 12.9 No   
  1. * At initiation of treatment, SAEs = Severe adverse events grade III/IV
  2. ** After HAART initiation